Levetiracetam Actavis

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

levetiracetam

Available from:

Actavis Group PTC ehf

ATC code:

N03AX14

INN (International Name):

levetiracetam

Therapeutic group:

Antiepileptics,

Therapeutic area:

Epilepsy

Therapeutic indications:

Levetiracetam Actavis is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Actavis is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Product summary:

Revision: 19

Authorization status:

Authorised

Authorization date:

2011-10-03

Patient Information leaflet

                                53
B. PACKAGE LEAFLET
54
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
_ _
LEVETIRACETAM ACTAVIS 250 MG FILM-COATED TABLETS
LEVETIRACETAM ACTAVIS 500 MG FILM-COATED TABLETS
LEVETIRACETAM ACTAVIS 750 MG FILM-COATED TABLETS
LEVETIRACETAM ACTAVIS 1000 MG FILM-COATED TABLETS
levetiracetam
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD START
TAKING THIS MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Levetiracetam Actavis is and what it is used for
2.
What you need to know before you take Levetiracetam Actavis
3.
How to take Levetiracetam Actavis
4.
Possible side effects
5.
How to store Levetiracetam Actavis
6.
Contents of the pack and other information
1.
WHAT LEVETIRACETAM ACTAVIS IS AND WHAT IT IS USED FOR
Levetiracetam is an antiepileptic medicine (a medicine used to treat
seizures in epilepsy).
Levetiracetam Actavis is used:
•
on its own in adults and adolescents from 16 years of age with newly
diagnosed epilepsy, to
treat a certain form of epilepsy. Epilepsy is a condition where the
patients have repeated fits
(seizures). Levetiracetam is used for the epilepsy form in which the
fits initially affect only one
side of the brain, but could thereafter extend to larger areas on both
sides of the brain (partial
onset seizure with or without secondary generalisation). Levetiracetam
has been given to you by
your doctor to reduce the number of fits.
•
as an add-on to other antiepileptic medicines to treat:
•
partial onset seizures with or without generalisation in adults,
adolescents, children and
infants from one month of age;
•
myoclonic seizu
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Levetiracetam Actavis 250 mg film-coated tablets
Levetiracetam Actavis 500 mg film-coated tablets
Levetiracetam Actavis 750 mg film-coated tablets
Levetiracetam Actavis 1000 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Levetiracetam Actavis 250 mg film-coated tablets
Each film-coated tablet contains 250 mg levetiracetam.
Levetiracetam Actavis 500 mg film-coated tablets
Each film-coated tablet contains 500 mg levetiracetam.
Levetiracetam Actavis 750 mg film-coated tablets
Each film-coated tablet contains 750 mg levetiracetam.
Excipient with known effect:
Each film-coated tablet contains 0.156 mg sunset yellow E110.
Levetiracetam Actavis 1000 mg film-coated tablets
Each film-coated tablet contains 1000 mg levetiracetam.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Levetiracetam Actavis 250 mg film-coated tablets
Oval, light blue, 13.6 x 6.4 mm marked with “L” on one side and
“250” on the other side.
Levetiracetam Actavis 500 mg film-coated tablets
Oval, yellow, 17.1 x 8.1 mm marked with “L” on one side and
“500” on the other side.
Levetiracetam Actavis 750 mg film-coated tablets
Oval, orange 19.0 x 9.3 mm marked with “L” on one side and
“750” on the other side.
Levetiracetam Actavis 1000 mg film-coated tablets
Oval, white, 19.0 x 10.0 mm marked with “L” on one side and
“1000” on the other side.
4.
CLINICAL PARTICULARS
3
4.1
THERAPEUTIC INDICATIONS
Levetiracetam Actavis is indicated as monotherapy in the treatment of
partial onset seizures with or
without secondary generalisation in adults and adolescents from 16
years of age with newly diagnosed
epilepsy.
Levetiracetam Actavis is indicated as adjunctive therapy
•
in the treatment of partial onset seizures with or without secondary
generalisation in adults,
adolescents, children and infants from 1 month of age with epilepsy.
•
in the treatment of myoclonic seizures in adults
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 22-06-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 22-06-2023
Public Assessment Report Public Assessment Report Bulgarian 07-09-2021
Patient Information leaflet Patient Information leaflet Spanish 22-06-2023
Public Assessment Report Public Assessment Report Spanish 07-09-2021
Patient Information leaflet Patient Information leaflet Czech 22-06-2023
Public Assessment Report Public Assessment Report Czech 07-09-2021
Patient Information leaflet Patient Information leaflet Danish 22-06-2023
Public Assessment Report Public Assessment Report Danish 07-09-2021
Patient Information leaflet Patient Information leaflet German 22-06-2023
Public Assessment Report Public Assessment Report German 07-09-2021
Patient Information leaflet Patient Information leaflet Estonian 22-06-2023
Public Assessment Report Public Assessment Report Estonian 07-09-2021
Patient Information leaflet Patient Information leaflet Greek 22-06-2023
Public Assessment Report Public Assessment Report Greek 07-09-2021
Patient Information leaflet Patient Information leaflet French 22-06-2023
Public Assessment Report Public Assessment Report French 07-09-2021
Patient Information leaflet Patient Information leaflet Italian 22-06-2023
Public Assessment Report Public Assessment Report Italian 07-09-2021
Patient Information leaflet Patient Information leaflet Latvian 22-06-2023
Public Assessment Report Public Assessment Report Latvian 07-09-2021
Patient Information leaflet Patient Information leaflet Lithuanian 22-06-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 22-06-2023
Public Assessment Report Public Assessment Report Lithuanian 07-09-2021
Patient Information leaflet Patient Information leaflet Hungarian 22-06-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 22-06-2023
Public Assessment Report Public Assessment Report Hungarian 07-09-2021
Patient Information leaflet Patient Information leaflet Maltese 22-06-2023
Public Assessment Report Public Assessment Report Maltese 07-09-2021
Patient Information leaflet Patient Information leaflet Dutch 22-06-2023
Public Assessment Report Public Assessment Report Dutch 07-09-2021
Patient Information leaflet Patient Information leaflet Polish 22-06-2023
Public Assessment Report Public Assessment Report Polish 07-09-2021
Patient Information leaflet Patient Information leaflet Portuguese 22-06-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 22-06-2023
Public Assessment Report Public Assessment Report Portuguese 07-09-2021
Patient Information leaflet Patient Information leaflet Romanian 22-06-2023
Public Assessment Report Public Assessment Report Romanian 07-09-2021
Patient Information leaflet Patient Information leaflet Slovak 22-06-2023
Public Assessment Report Public Assessment Report Slovak 07-09-2021
Patient Information leaflet Patient Information leaflet Slovenian 22-06-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 22-06-2023
Public Assessment Report Public Assessment Report Slovenian 07-09-2021
Patient Information leaflet Patient Information leaflet Finnish 22-06-2023
Public Assessment Report Public Assessment Report Finnish 07-09-2021
Patient Information leaflet Patient Information leaflet Swedish 22-06-2023
Public Assessment Report Public Assessment Report Swedish 07-09-2021
Patient Information leaflet Patient Information leaflet Norwegian 22-06-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 22-06-2023
Patient Information leaflet Patient Information leaflet Icelandic 22-06-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 22-06-2023
Patient Information leaflet Patient Information leaflet Croatian 22-06-2023
Public Assessment Report Public Assessment Report Croatian 07-09-2021

Search alerts related to this product